Wegovy Shows Increased Reports of Blinding Condition in FDA Data Analysis

Semaglutide prescribed for weight loss (Wegovy) showed increased reports of a rare blinding condition compared to other GLP-1 medications, according to analysis of FDA adverse event data published in MedPage Endocrinology.

The analysis found that Wegovy was associated with higher rates of reported ischemic optic neuropathy (ION) cases than other GLP-1 receptor agonists, including the same semaglutide molecule prescribed for diabetes (Ozempic). ION is a condition that can cause sudden, permanent vision loss when blood flow to the optic nerve is blocked.

The distinction between Wegovy and Ozempic is particularly notable since both contain identical semaglutide molecules. Wegovy is prescribed at higher doses for weight loss — up to 2.4mg weekly compared to Ozempic's maximum 2mg weekly for diabetes management. However, the researchers noted that dosing differences alone may not fully explain the disparity in ION reports.

The elevated reporting pattern was specific to the obesity indication, not seen with semaglutide prescribed for diabetes or with other GLP-1 receptor agonists like tirzepatide (Mounjaro, Zepbound) or liraglutide (Saxenda).

ION typically affects people over 50 and those with conditions like diabetes, high blood pressure, and sleep apnea — health issues that often overlap with obesity. The condition causes sudden, painless vision loss that usually cannot be reversed. While rare, occurring in roughly 2 to 10 people per 100,000 annually, ION represents one of the few ophthalmologic emergencies that can result in permanent disability.

The FDA analysis examined spontaneous adverse event reports, which have inherent limitations. These databases capture events reported by healthcare providers and patients but cannot establish definitive causation or provide precise risk calculations. Reporting patterns may also vary between different patient populations and prescribing contexts.

Earlier research has identified potential associations between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), the most common form of ION, though those studies focused on diabetic populations rather than weight-loss patients.

What This Means for Patients

People taking or considering Wegovy should discuss this potential risk with their healthcare providers, particularly if they have existing cardiovascular risk factors or are over 50. The absolute risk remains low, but patients should be aware of ION's warning signs: sudden, painless vision loss, often described as a "curtain coming down" over part of the visual field.

This doesn't necessarily mean avoiding Wegovy, but rather ensuring informed decision-making. For many patients, the cardiovascular and metabolic benefits of significant weight loss may outweigh this rare risk. However, those with multiple risk factors for ION might want to discuss alternative approaches with their doctors.

Current Wegovy users should maintain regular eye exams and report any sudden vision changes immediately to their healthcare provider.